Hubei Guangji Pharmaceutical Co Ltd (000952) — Cash Flow-to-Debt Ratio
Hubei Guangji Pharmaceutical Co Ltd (000952) has a Cash Flow-to-Debt Ratio of 0.01x as of September 2025, meaning its operating cash flow of CN¥22.38 Million could theoretically repay 0% of its total liabilities (CN¥1.62 Billion) in one year. See Hubei Guangji Pharmaceutical Co Ltd free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Hubei Guangji Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio (1998–2024)
Historical debt coverage capacity for Hubei Guangji Pharmaceutical Co Ltd across 27 annual periods. Also explore 000952 year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Hubei Guangji Pharmaceutical Co Ltd (1998–2024)
Year-by-year debt coverage analysis for Hubei Guangji Pharmaceutical Co Ltd. For market capitalisation and broader financial context, see Hubei Guangji Pharmaceutical Co Ltd (000952) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.00x | CN¥655.36K | CN¥1.72 Billion | ▲ +100.4% |
| 2023 | -0.09x | CN¥-148.96 Million | CN¥1.64 Billion | ▼ -297.3% |
| 2022 | 0.05x | CN¥45.08 Million | CN¥977.25 Million | ▼ -63.7% |
| 2021 | 0.13x | CN¥75.91 Million | CN¥598.09 Million | ▼ -34.8% |
| 2020 | 0.19x | CN¥119.38 Million | CN¥613.75 Million | ▲ +8.2% |
| 2019 | 0.18x | CN¥144.20 Million | CN¥802.21 Million | ▼ -36.9% |
| 2018 | 0.28x | CN¥231.44 Million | CN¥812.33 Million | ▲ +39.7% |
| 2017 | 0.20x | CN¥178.83 Million | CN¥876.65 Million | ▲ +19.0% |
| 2016 | 0.17x | CN¥167.07 Million | CN¥974.70 Million | ▲ +669.0% |
| 2015 | -0.03x | CN¥-33.35 Million | CN¥1.11 Billion | ▲ +56.6% |
| 2014 | -0.07x | CN¥-74.69 Million | CN¥1.08 Billion | ▼ -159.5% |
| 2013 | 0.12x | CN¥95.16 Million | CN¥816.78 Million | ▼ -14.2% |
| 2012 | 0.14x | CN¥108.02 Million | CN¥795.93 Million | ▲ +6.6% |
| 2011 | 0.13x | CN¥81.88 Million | CN¥643.07 Million | ▼ -10.1% |
| 2010 | 0.14x | CN¥77.18 Million | CN¥545.06 Million | ▲ +383.2% |
| 2009 | -0.05x | CN¥-24.35 Million | CN¥486.93 Million | ▼ -109.0% |
| 2008 | 0.56x | CN¥220.70 Million | CN¥395.78 Million | ▼ -45.3% |
| 2007 | 1.02x | CN¥331.98 Million | CN¥325.76 Million | ▲ +148.7% |
| 2006 | 0.41x | CN¥125.95 Million | CN¥307.34 Million | ▲ +165.5% |
| 2005 | 0.15x | CN¥54.14 Million | CN¥350.68 Million | ▲ +1909.2% |
| 2004 | -0.01x | CN¥-3.32 Million | CN¥388.76 Million | ▲ +80.5% |
| 2003 | -0.04x | CN¥-15.40 Million | CN¥352.38 Million | ▼ -118.0% |
| 2002 | 0.24x | CN¥76.20 Million | CN¥313.05 Million | ▲ +398.8% |
| 2001 | -0.08x | CN¥-22.40 Million | CN¥274.96 Million | ▼ -132.7% |
| 2000 | 0.25x | CN¥48.57 Million | CN¥194.67 Million | ▼ -27.4% |
| 1999 | 0.34x | CN¥68.57 Million | CN¥199.49 Million | ▲ +520.0% |
| 1998 | -0.08x | CN¥-15.29 Million | CN¥186.80 Million | — |